Article
Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
Antiviral therapy - 1 Jan 2015
Aloia Amanda L, Eyre Nicholas S, Black Stuart, Bent Stephen J, Gaeguta Adriana, Guo Zhuyan, Narayana Sumudu K, Chase Robert, Locarnini Stephen, Carr Jill M, Howe John A, Beard Michael R
Abstract excerpt
BACKGROUND: Genotype (gt)6 HCV is common amongst HCV-positive populations of the Asia-Pacific region but cell culture models for this gt have only recently been developed. Boceprevir (SCH503034) is a clinically available inhibitor of the HCV NS3 protein. We investigated the efficacy of boceprevir for inhibiting replication of a chimeric gt1b replicon encoding a gt6a NS3 protease and defined the development of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.